Second annual meeting of the ISP
Leslie Sheffield begins this issue with a report (pp 144-145) on the International Society of Pharmcogenomics' (ISP) second annual meeting from 2-3 November 2003 in Los Angeles, CA, USA. The conference was held in association with the Pacific Rim Association for Clinical Pharmacogenetics, and presentations focused on the pharmacogenomics of drugs in clinical practice, gene mapping, HapMap developments, and updates on the search for novel drug targets. Speakers included Magnus Ingleman-Sundberg, Urs Meyer, Olivier Grenet, Tamas Bartfai, and others presenting at the conclave's four symposia.
Third annual meeting of the ISP
The island of Santorini, Greece played host to the ISP's third annual meeting, entitled 'From Human Genetic Variations to Prediction of Risks and Responses to Drugs and to the Environment' (1-4 October 2004). As a collaborative effort with the International Union of Nutritional Sciences, the meeting aimed to bring together clinicians and scientists from academia and industry to discuss how genome variation plays a role in drug response and nutrition. Leslie Sheffield's bulletin (pp 146-148) features session highlights of the broad range of topics discussed, including cardiovascular disease, nutrigenomics, cancer pharmacogenomics, drug targets, neurological disorders and proteomics.
Drug response and HapMap
Information on DNA sequence variation is crucial for elucidating the genetic basis for variable drug response. The International HapMap Project promises to yield a mass of such data, but statistical tools are still needed to relate genes to pharmacologic effects. Drug response is a dynamic process, and any quantification of it requires consideration of concentration, dose, and time course. Lin et al (pp 149-156) address this need by proposing a novel statistical model for determining specific DNA sequences that are associated with variation in drug response. The authors further gird their proposal using an example of the statistical method applied to a pharmacogenetic study of cardiovascular disease.
Genetic variation of CNT3
Variability of response to cancer chemotherapy is a major clinical problem. Badagnani et al (pp 157-165) consider this obstacle in light of the human concentrative nucleoside transporter CNT3, which plays an important role in mediating the entry of many anticancer nucleoside analog drugs. CNT3 belongs to the SLC28 concentrative nucleoside transporter family, and it is primarily responsible for the transport of several antileukemia drugs. Research also suggests that it has the highest interindividual variability. The authors of this paper identify and analyze the genetic variation in SLC28A3, and also examine the genetic and functional diversity of CNT3.
Nicotine dependence, linkage evidence
Epidemiological studies have demonstrated that genetics accounts for at least 50% of liability to nicotine dependence, the most prevalent form of drug addiction in the world. However, linkage studies demonstrating convincing evidence for susceptibility loci are very limited. In order to find evidence of significant linkage regions, Wang et al (pp 166-172) conducted genome-wide permutation analyses on smoking data collected in the Framingham Heart Study, one of the largest existing data sets containing smoking-related information. Using a computationally intense permutation test, the authors identified 10 genomic regions that may harbor susceptibility loci for nicotine dependence.
Characterizing novel CYP2D6 variations
Cytochrome P4502D6 (CYP2D6) is implicated in the metabolism of several clinically available drugs. The CYP2D6 gene locus, however, is highly polymorphic, with the result that CYP2D6 activity ranges widely within a population. Genotyping studies have found that the presence of a nonfunctional or unstable enzyme predicts a poor metabolizer phenotype in Caucasians, but less so for African-Americans. In evaluating the discordance found in phenotype to genotype correlation studies, Gaedigk et al (pp 173-182) describe the identification and functional characterization of novel CYP2D6 allelic variants discovered in African-American subjects.
Variability in candidate genes for drug response
Pharmacogenetic studies require a thorough knowledge of DNA sequence variation in candidate genes. Variants with influence on drug response can be extremely common or rare-the trick is to identify them and characterize their contribution. Freudenberg-Hua et al (pp 183-192) employ a resequencing approach to describe sequence variability for a set of 111 genes whose products may be implicated in variations in drug response. The authors observe that functionally relevant variants are found at lower frequencies in a population, thus pointing the way for investigations of the genetic causes of severe side effects.
CYP2C9 and warfarin metabolism
Warfarin, an oral anticoagulant with high interindividual variability in dose requirement, is clinically available as a mixture of equal parts S-and R-warfarin. S-warfarin is metabolized mainly by cytochrome P4502C9. Herman et al (pp 193-202) address the influence of CYP2C9 allelic variations on both dose requirement and metabolism of the drug. Their multiple regression analysis demonstrates that CYP2C9 genotype, concomitant treatment with warfarin metabolism inducers, and lean body weight all significantly contribute to warfarin dose requirement and Swarfarin metabolism.
Proteomics and psychostimulant addiction
Rats given continuous access to d-amphetamine (d-AMPH) will fall into a cycle of selfadministration, voluntary abstinence, and relapse back to self-administration-a typical use pattern seen in human drug abusers. Understanding the neurobiological substrates mediating the transition from one behavioral phase to another is critical to the development of more effective treatment strategies. To this end, Freeman et al (pp 203-214) present results from a study conducted to examine the proteomic changes in the hippocampus during the d-AMPH binge-abstinence-relapse cycle. Their results demonstrate the applicability of quantitative proteomic technologies to behavioral pharmacology research. 
